Safe Use of Dolutegravir (DTG) by Women and Girls of Child-bearing Potential: A Decision-making Tool
2019 — This tool uses a life-cycle approach and decision-making tree for HIV treatment providers to guide women and girls of child-bearing potential through decisions related to the initiation of a Dolutegravir (DTG)-based antiretroviral regimen. Because of the concern that exposure to DTG at the time of conception or during the first 8 weeks of pregnancy may be associated with neural tube defect among infants, providers need to be able to counsel women about this possible risk.
The tool follows the World Health Organization's Interim Guidance (2018) on antiretroviral regimens for treating and preventing HIV infection. It was produced by FHI 360 under the Advancing Partners and Communities (APC) project in collaboration with the Uganda Communication for Healthy Communities (CHC) project, the U.S. Agency for International Development and the U.S. Centers for Disease Control and Prevention (CDC).